VLX1570

Asset

Inhibits 19S proteasome deubiquitinases USP14 and UCHL5, inducing proteotoxic stress and apoptosis.

Stage: Phase 1
Modality: Small molecule
Target: Apoptosis; 1
Indication: 2,129
Trials: 1
Developer

Indications

1

Multiple myeloma
Phase 1, Terminated, NCT02372240, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains5
Owner and partners1
Trials2,129
Evidence for its targets5
Competitors9
Aging relevance1
Signals3

Every asset’s record: target, stage, trials and the evidence behind it.